Alnylam Lays Out 2030 Vision, Bets On TTR Leadership And Pipeline Scale

Benzinga_recent_news01-13

Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) announced a new five-year roadmap, "Alnylam 2030," on Sunday, outlining the company’s focus on scaling its operations. The strategy builds on the company's ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2603528798?lang=en_US&edition=fundamental","thumbnail":"https://cdn.benzinga.com/files/images/story/2026/01/12/Alnylam-Pharmaceuticals-Photo-via-Shutte.jpeg?optimize=medium&dpr=2&auto=webp&width=240","is_english":true,"pubTime":"2026-01-13 02:33","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2603528798","market":"us","top_or_hot":-1,"title":"Alnylam Lays Out 2030 Vision, Bets On TTR Leadership And Pipeline Scale","media":"Benzinga_recent_news","content":"<div>\n<p>Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) announced a new five-year roadmap, \"Alnylam 2030,\" on Sunday, outlining the company’s focus on scaling its operations.\nThe strategy builds on the company's ...</p>\n\n<a href=\"https://www.benzinga.com/markets/guidance/26/01/49855001/alnylam-lays-out-2030-vision-bets-on-ttr-leadership-and-pipeline-scale\">Source Link</a>\n\n</div>\n","source":"benzinga_recent_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Alnylam Lays Out 2030 Vision, Bets On TTR Leadership And Pipeline Scale</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAlnylam Lays Out 2030 Vision, Bets On TTR Leadership And Pipeline Scale\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-01-13 02:33 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.benzinga.com/markets/guidance/26/01/49855001/alnylam-lays-out-2030-vision-bets-on-ttr-leadership-and-pipeline-scale><strong>Benzinga_recent_news</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) announced a new five-year roadmap, \"Alnylam 2030,\" on Sunday, outlining the company’s focus on scaling its operations.\nThe strategy builds on the company's ...</p>\n\n<a href=\"https://www.benzinga.com/markets/guidance/26/01/49855001/alnylam-lays-out-2030-vision-bets-on-ttr-leadership-and-pipeline-scale\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4588","symbol_name":"碎股","start_time":0,"source_url":"https://www.benzinga.com/markets/guidance/26/01/49855001/alnylam-lays-out-2030-vision-bets-on-ttr-leadership-and-pipeline-scale","article_id":"2603528798","we_media_id":null,"thumbnails":["https://cdn.benzinga.com/files/images/story/2026/01/12/Alnylam-Pharmaceuticals-Photo-via-Shutte.jpeg?optimize=medium&dpr=2&auto=webp&width=240"],"rights":{"source":"benzinga_recent_news","url":"https://www.benzinga.com/markets/guidance/26/01/49855001/alnylam-lays-out-2030-vision-bets-on-ttr-leadership-and-pipeline-scale","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2603528798","pubTimestamp":1768242780,"columns":[],"sourceInfo":{"source_id":"benzinga_recent_news","name":"Benzinga"},"weMediaInfo":null,"summary":"Alnylam outlines its 2030 strategy, targeting TTR leadership, pipeline expansion, and strong revenue growth backed by rising product sales.","collect":0,"end_time":0,"defaultTopTitle":"benzinga.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4588":"碎股","LU0889565916.HKD":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC","LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD","BK4585":"ETF&股票定投概念","LU0882574055.USD":"富达全球健康医疗A ACC","ALNY":"阿尔尼拉姆制药公司","BK4548":"巴美列捷福持仓","BK4139":"生物科技","LU0114720955.EUR":"SUSTAINABLE GLOBAL HEALTH CARE \"A\" INC","LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)"},"translate_title":"Alnylam制定2030年愿景，押注TTR领导地位和管道规模","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ALNY":1},"content_text":"Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) announced a new five-year roadmap, \"Alnylam 2030,\" on Sunday, outlining the company’s focus on scaling its operations.\nThe strategy builds on the company's history of setting and meeting long-term goals, following the completion of its prior P5x25 plan. Management said Alnylam has met or exceeded all previous five-year objectives, setting the stage for its next phase of expansion.\nAt the core of Alnylam 2030 is a push to establish durable global leadership in transthyretin, or TTR, diseases. The company aims to lead the TTR market in revenue by 2030 and cumulatively over the next five years. \nA key component of that plan is the expected launch of nucresiran, a next-generation RNAi therapy, in polyneuropathy by 2028 and cardiomyopathy by 2030.\nBeyond TTR, Alnylam plans to deliver at least two additional transformative medicines with blockbuster potential outside of TTR indications, expand its reach to 10 tissue types, and run more than 40 clinical programs. Alnylam also intends to reinvest roughly 30% of revenue into non-GAAP research and development.\nBy the end of 2030, Alnylam is targeting more than 25% total revenue compound annual growth and a non-GAAP operating margin of around 30%.\nAlnylam reported preliminary net product revenue for Amvuttra and Onpattro reached about $827 million and $32 million in the fourth quarter, driving 151% year-over-year growth for the TTR franchise.\nFor the full year 2025, Amvuttra and Onpattro reached about $2.3 billion and $173 million, respectively, more than doubling from 2024.\nRare disease products Givlaari and Oxlumo posted fourth-quarter revenues of roughly $137 million combined, with full-year sales of about $499 million.\nLooking ahead, Alnylam guided for 2026 combined net product revenue of $4.9 billion to $5.3 billion, reflecting 71% growth at the midpoint. By franchise, the company expects:\nWilliam highlighted that 2025 net product revenues were narrowly below their and Street estimates, while 2026 net product revenue guidance is significantly above the estimates.\nALNY Price Action: Alnylam Pharmaceuticals shares were down 10.07% at $358.20 at the time of publication on Monday, according to Benzinga Pro data.\nPhoto via Shutterstock","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2603528798","isCrawlerRequest":true}